Enjaymo

FDA approves Enjaymo™ (sutimlimab-jome), first  treatment for use in patients with cold agglutinin disease. Enjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system.